Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | MAOA | P21397 | 17/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327984 | 0.87 | MAOA (0.65) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL4899222 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL4929112 | 0.84 | CYP3A4 (0.69) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL3325038 | 0.81 | MAOA (0.60) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL5515504 | 0.81 | MAOA (0.56) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL3328025 | 0.80 | MAOA (0.55) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL14436450 | 0.80 | MAOA (0.55) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL5522189 | 0.80 | MAOA (0.55) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL3326296 | 0.79 | MAOA (0.56) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL5519710 | 0.78 | MAOA (0.53) | CYP3A4CYP2D6MAOAMAOBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080021071-A1 | 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| CN-1989134-A | 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents | ASTRAZENECA AB (SE) | 2007-06-27 | — | — | CN | disclosed |
| EP-1753755-A1 | 3- {4- (PYRIDIN-3-YL) PHENYL} -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | H1-3, H1-0, MRPL21 | CYP3A4 420/4885CYP2D6 155/4885MAOA 2336/4885 |
| US-20080021071-A1 | 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | MRPL21, ARG1, OXA1L | CYP3A4 69/4885CYP2D6 97/4885MAOA 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.